Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths
Key Points:
1. Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial.
2. AML patients showed early signs of benefit, but safety concerns led to an immediate stop.
On August 14, 2025, Schrödinger announced it will halt development of its CDC7 inhibitor SGR-2921 after two treatment-related deaths in a Phase 1 trial for acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes. CDC7 is a kinase essential for DNA replication, and its inhibition aims to disrupt uncontrolled cancer cell growth. AML affects around 20,000 Americans each year and remains one of the most difficult hematologic malignancies to treat. While some trial participants showed early signs of clinical benefit, the severity of adverse events prompted an immediate risk–benefit reassessment. The company’s official statement confirmed all patients will transition to alternative therapies. Scientific literature on CDC7 inhibition notes the narrow safety margin associated with such agents. Schrödinger’s stock dropped sharply following the news. The decision underscores the risks inherent in first-in-class oncology trials, particularly in small, heavily pretreated patient populations. The company will now shift focus to other oncology and immunology candidates in its pipeline. Early termination of oncology programs is not uncommon, but such decisions often prompt deeper investigation into target biology and trial design. Safety boards will review whether certain patient subgroups were at elevated risk and if biomarkers could have predicted adverse outcomes. For the research community, the halt serves as a cautionary tale about balancing innovation with patient safety in first-in-human studies. This event may also influence how regulators evaluate future CDC7-targeted candidates. While the setback is significant for Schrödinger, it could help refine the field’s understanding of DNA replication inhibitors and their potential role in cancer therapy.
Image: PD
©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
